To the Editor.—In the May issue of the Archives, Gundry and coworkers described treatment of Hürthle cell neoplasms of the thyroid.1 Our experience in this field is at odds with their conclusion.
First, Gundry et al incorrectly cited some data from a previous report by us2 on this subject. At the time of our evaluation, we had no (not two) deaths from oxyphil (Hürthle cell) carcinoma in our surgically treated patients. The two deaths mentioned in our report affected patients who received radiotherapy only. Furthermore, we did a complete follow-up of all 42 surgically treated patients (not only 34). Regarding the seven patients who were dead at follow-up, careful autopsy examinations gave definite answers as to their outcome. Moreover, three (not five) of seven patients with histologically malignant tumors were followed up for less than four years. The accurate figures appear clearly in our report.
BONDESON L, BONDESON A, LJUNGBERG O. Treatment of Hürthle Cell Neoplasms of the Thyroid. Arch Surg. 1983;118(12):1453. doi:10.1001/archsurg.1983.01390120073028